| Douglas W Davidson, | |
|
12525 Perkins Road, Suite B, Baton Rouge, LA 70810 | |
| (225) 819-8857 | |
| (225) 767-6822 |
| Full Name | Douglas W Davidson |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 12525 Perkins Road, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982790697 | NPI | - | NPPES |
| P00392505 | Other | LA | RRM |
| 1098299 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 010156 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Douglas W Davidson, 7777 Hennessy Blvd, Suite 1004 154, Baton Rouge, LA 70808 Ph: (225) 214-9352 | Douglas W Davidson, 12525 Perkins Road, Suite B, Baton Rouge, LA 70810 Ph: (225) 819-8857 |
News Archive
Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that its product candidate CRTX-067 is an ANDA filing for a generic 10 mg chlorpheniramine polistirex/8 mg hydrocodone polistirex suspension product that will be a generic substitute for the product currently sold under the Tussionex brand name by UCB, Inc.
Most grade school students are likely to claim recess as their favorite period of the day; however, in many cases recess still can be sedentary with students not engaging in enough physical activity.
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
Researchers in Sweden have challenged the interpretation that variable non-pharmaceutical interventions (NPIs) and "herd immunity" protection are responsible for the rise and fall of coronavirus disease 2019 (COVID-19) epidemic waves in hard-hit locations where authorities have not enforced strict NPIs.
Diabetic retinopathy is one of the main vascular complications of type 2 diabetes, and the most common cause of visual deterioration in adults.
› Verified 2 days ago
Dr. Lorenza Marie Winn, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 8220 Goodwood Blvd Ste 2a, Baton Rouge, LA 70806 Phone: 225-231-7072 Fax: 225-231-7078 | |
Dr. Dawn R Marcelle, M.D., M.P.H. General Practice Medicare: Not Enrolled in Medicare Practice Location: 3140 Florida Blvd, Capitol City Family Health Center, Baton Rouge, LA 70806 Phone: 225-650-2000 Fax: 225-650-2099 | |
Gary Brandt, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 9422 Scotland Ave, Baton Rouge, LA 70807 Phone: 225-774-1822 Fax: 225-774-1836 | |
Mrs. Abigail Marie Shoenfelt, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 8416 Cumberland Pl, Baton Rouge, LA 70806 Phone: 225-252-3565 Fax: 985-781-4319 | |
Dr. Jennifer Lynn Miatech, MD General Practice Medicare: Medicare Enrolled Practice Location: 8585 Picardy Ave., Medical Tower 2, Baton Rouge, LA 70808 Phone: 225-819-1120 | |
Jimmy Nooe Guidry, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 8742 Goodwood Blvd, Baton Rouge, LA 70806 Phone: 225-231-7070 Fax: 225-231-7069 | |
Marian Lorraine Bellecci, MD General Practice Medicare: Medicare Enrolled Practice Location: 3333 Drusilla Ln, Suite A, Baton Rouge, LA 70809 Phone: 225-924-3906 Fax: 225-924-3906 |